Clinical Trials Logo

Clinical Trial Summary

Infection of the ascitic fluid is a serious complication associated with high morbidity and mortality. This fluid is often colonized with bacteria that can cause infection of the peritoneum and possibly sepsis. Many bacteria of the human intestinal microbiome can't be cultured by standard methods; therefore it seems likely that many of the relevant bacteria are not discovered in routine diagnostics, but may be relevant to pathogenesis. Culture-independent approaches such as NGS (Next generation Sequencing) have in principle made it possible to study or prove complex microbial colonization. Because NGS is a relatively new technology, microbiological diagnostic protocols need to be further customized and refined to integrate with the standard diagnostic workflow, if necessary. For microbiological diagnostics, material is collected from the appropriate ascites patients and sent for microbiological diagnostics. Afterwards the cultural diagnostics are carried out as part of the patient care at the university hospital. In this study the investigators plan to use these samples to analyze and compare the presence of bacteria by NGS in parallel to the culture diagnostics, and then compare it to the patients' gut microbiome, to understand the possible effect of the microbiome on ascites pathogenesis and outcome.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04131751
Study type Observational
Source University Hospital Freiburg
Contact
Status Completed
Phase
Start date October 1, 2019
Completion date October 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT05621005 - Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients Phase 2
Recruiting NCT05352152 - Application of NGS in Ascites Infection
Recruiting NCT04125654 - Metagenomic Next-Generation Sequencing for Diagnosis of Ascites Infection in End-stage Liver Diseases N/A